Author

Jian-Jun Gao

h-index 7 View on Semantic Scholar

We have 2 of 18 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma.

Advanced pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with limited benefits from conventional chemotherapy. Daraxonrasib is an oral, noncovalent RAS(ON) multi-selective inhibitor that forms a ternary complex with cyclophilin A and GTP-bound RAS, blocking downstream signaling across multiple mutant and...

Yue-Yi Sun, Chen Pang, Jian-Jun Gao · Drug Discoveries & Therapeut... · 0 citations

Open access Aug 2026

Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia.

The ongoing CORALreef Outcomes trial will determine whether enlicitide-mediated LDL-C reduction translates into fewer major cardiovascular events and will help define its long-term clinical role.

Yue-Yi Sun, Jian-Jun Gao · Drug Discoveries & Therapeut... · 0 citations